1. Bodley, A. L. and Liu, L. F. Topoisomerases as novel targets for cancer chemotherapy.Biotechnology, 6, 1315–1319 (1988).
2. Creaven, P. J., Allen, L. M. and Muggia, F. M. Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: relation to dose and toxicity.Cacer, Chemother. Rep., 56, 573–576 (1972).
3. Drewinko, B., Freireich, E. J. and Gottlieb, J. A. Lethal activity of camptothecin sodium on human lymphoma cells.Cancer Res., 34, 747–750 (1974).
4. Giovanella, B. C., Stehlin, J. S., Wall, M. E., Wani, M. C., Nicholas, A. W., Liu, L. F., Silber, R. and Potmesil, M. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts.Science, 246, 1046–1048 (1989).
5. Gottlieb, J. A., Guarino, A. M., Call, J. B., Oliverio, V. and Block, J. B., Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880).Cancer Chemother. Rep., 54, 461–470 (1970).